Neurobiologic Insights into Major Depressive Disorder: Emerging Therapies with Novel MOAs
Dr. Roger S. McIntyre: Major Depressive Disorder and Bipolar Disorder
Just How Bad Is Alkermes' FDA Depression Drug Setback?
Why Alkermes' Depression Drug Stumbled, and How Illumina Plans to Profit from M&A
Alkermes Antidepressant Rejected by FDA | ALKS 5461
Samidorphan, also known as 3-carboxamido-4-hydroxynaltrexone, is an opioid antagonist that preferentially acts as an antagonist of the μ-opioid receptor (MOR). It is under development by Alkermes for the treatment of major depressive disorder and possibly other psychiatric conditions.